iquid biopsy in metastatic brain tumours
Not Applicable
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2024/07/071572
- Lead Sponsor
- Exsegen Genomics Research Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Subjects with suspected primary or secondary brain tumor on neuroimaging
2. Age-any age with proper consent/assent
3. Provision of signed and dated informed consent form; by patient or guardian/parent
4. Stated willingness to comply with all study procedures
Exclusion Criteria
Patients who fail to meet all of the above criteria for cases will be excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ability to distinguish between a secondary malignant neoplasm and a non-malignant condition using a liquid biopsy test, with an accuracy approaching the traditional biopsy.Timepoint: Baseline, 12 weeks, 26 weeks and 52 weeks
- Secondary Outcome Measures
Name Time Method 1. Ability to distinguish between the secondary neoplasm & other primary malignant neoplasms of the brain. <br/ ><br> <br/ ><br>2. Ability to diagnose the possible site of the primary neoplasm from which the secondary malignant brain neoplasm has arisen.Timepoint: Baseline, 12 weeks, 26 weeks & 52 weeks